Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292666 · ClinicalTrials.gov registry record
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
A clinical trial of Venous Thromboembolism and Anticoagulants and Bleeding Disorders, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 39,603
- Enrollment target
- 2
- Study locations
NCT03292666: Completed study of Venous Thromboembolism and Anticoagulants and Bleeding Disorders, sponsored by University of California, San Francisco.
NCT03292666 is a study of Venous Thromboembolism and Anticoagulants and Bleeding Disorders that has completed, run by University of California, San Francisco. The registered enrollment target is 39,603 participants, above the 5,453-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (626% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03292666, a study of Venous Thromboembolism and Anticoagulants and Bleeding Disorders, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 39,603 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcomes, such as quality-of-life, symptom burden, and treatment satisfaction. This information is crucial to helping clinicians and patients choose between various treatment options for venous thromboembolism in order to achieve the best possible balance between the risks, benefits, and impact on health.
Primary Outcome
Recurrent VTE will be defined as a new VTE encounter that is occurs after the index VTE event date. The encounter must represent a new diagnosis or symptomatology that is attributable to VTE.
Conditions Studied
Interventions
- DRUG Oral Anticoagulant
Study Locations (2)
California
- Kaiser Permanente Northern California - Oakland
- Kaiser Permanente Southern California - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39,603 participants |
| Start Date | 2010-01-01 |
| Est. Completion | 2022-06-21 |
What the finished NCT03292666 record still lists
NCT03292666 is an observational study that tracks outcomes without assigning an intervention. Its 39,603 participants enrollment target places it among the larger protocols in the corpus, above the 5,453-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (626% higher).
The record links to 2 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Oral Anticoagulant is the first listed.
NCT03292666 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03292666 about?
NCT03292666 is a clinical study titled "Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study". The proposed research seeks to provide insights on the contemporary epidemiology, treatment, and outcomes of VTE, including examining the uptake of new treatment strategies, the efficacy and safety of different anticoagulant options, and the impact of venous thromboembolism on patient-defined outcom...
What is the current status of trial NCT03292666?
This trial is currently completed. The enrollment target is 39,603 participants. The study started on 2010-01-01. Estimated completion is 2022-06-21.
What conditions does trial NCT03292666 study?
This clinical trial studies the following conditions: Venous Thromboembolism, Anticoagulants and Bleeding Disorders.
What interventions are being tested in trial NCT03292666?
The interventions under investigation include: Oral Anticoagulant (DRUG).
Who is sponsoring clinical trial NCT03292666?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03292666 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03292666's enrollment target sits among peer trials
39,603 2nd of 47 the highest of 47 other Venous Thromboembolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
RECRUITING
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
RECRUITING
-
Evaluation of the SCALED (SCaling AcceptabLE cDs)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI